Notícias

Regarded as defensive investments, consumer staples stocks are generally safe bets in choppy markets. The flip side is that they frequently fall behind growth industries when times are good, and this perception became a reality over the past six months as the sector was down 2.3% while the S&P 500 was up 10%.

FDA issues new regulatory guidance that supports commercialization of Philip Morris International's ZYN Ultra and IQOS in the U.S. The agency indicates it will not prioritize enforcement against nicotine pouch and e-vapor products with accepted premarket tobacco applications. This update reduces regulatory uncertainty around NYSE:PM smoke free products and is reflected in stronger Q1 results and improved sentiment among market participants. For investors watching NYSE:PM, this FDA shift...

The Standard & Poor's 500 index edged up 0.1% this week, its seventh consecutive weekly gain, as a s

Insightful Analysis of Jeff Auxier (Trades, Portfolio)'s First Quarter 2026 13F Filing

Shares of tobacco company Philip Morris International (NYSE:PM) jumped 5.6% in the afternoon session after the U.S. Food and Drug Administration (FDA) issued new guidance that signals a more favorable enforcement approach for certain nicotine products, which coincided with the company's recent report of a strong start to the year.

Both of Fox’s share classes were in yesterday’s top 10 bullish price surprises. In Fox’s case, its shares were up more than 7% due to a reasonably healthy quarterly report, suggesting more gains are in the cards. Here’s why.

Companies like Walmart, Costco, and Procter & Gamble face less risk of AI-related disruption than many other businesses.

If you are wondering whether Philip Morris International at around US$170.99 is offering fair value or asking too much, this breakdown will help you size up the stock with a clear, valuation focused lens. The stock closed at US$170.99, with returns of 1.1% over the last week, 6.6% over the last month, 6.7% year to date, 7.4% over the past year, 105.7% over three years and 122.3% over five years. This naturally raises questions about what is already reflected in the price. Recent coverage...

Despite Philip Morris’ weak performance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

These companies will offer reliable income for decades.

In late April 2026, Philip Morris International Inc. issued US$750,000,000 of 4.125% senior unsecured notes due 2029 and US$750,000,000 of 4.875% senior unsecured notes due 2036, alongside reporting first-quarter 2026 sales of US$10,146,000,000 and net income of US$2,438,000,000. These financing moves and results come as smoke-free products such as IQOS and ZYN approach roughly 39% of net revenues, reinforcing Philip Morris International’s shift toward a smoke-free business model and its...

Recent performance snapshot for Philip Morris International (PM) Philip Morris International (PM) has drawn fresh attention after recent share price moves, with the stock showing different returns over the past week, month and past 3 months that may interest income focused investors. See our latest analysis for Philip Morris International. With the share price at $169.19, Philip Morris International shows building short term momentum, with a 7 day share price return of 5.15% and 30 day share...

Philip Morris, Honeywell, Starbucks and United-Guardian highlight Zacks research as growth, innovation and segment strength drive recent performance.

Philip Morris, Honeywell and Starbucks stocks outperform peers as pricing power, aviation demand and turnaround efforts drive growth prospects.

These are three top consumer staples stocks to buy right now.

Philip Morris International’s fair value estimate has just been nudged down from US$195.17 to US$192.60, a small reset that still matters if you are tracking price targets closely. That shift comes as research houses pull in different directions, with some lifting targets into the US$200 range and others trimming them, reflecting a genuine split in how analysts view growth and execution. Read on to see what is driving those views and how you can keep up with the evolving narrative around the...